Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1033

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

OTHER: Placebo
DRUG: Remdesivir
DRUG: Baricitinib

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)